Glutaryl-CoA Dehydrogenase Deficiency

Mendelian MONDO:0009281 Pathograph 27 Organic Acidemia Inborn Error of Metabolism

Glutaryl-CoA dehydrogenase deficiency (historically termed glutaric aciduria type 1, GA1) is a rare autosomal recessive neurometabolic disorder caused by deficiency of glutaryl-CoA dehydrogenase (GCDH), which catalyzes the final step of lysine, hydroxylysine, and tryptophan catabolism. GCDH deficiency leads to accumulation of neurotoxic metabolites glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC). Untreated disease ranges from infantile-onset to later-onset forms (after age six years). Affected individuals are at highest risk for acute encephalopathic crises in early childhood (especially ages 3-36 months), often triggered by catabolic stress, which cause irreversible bilateral striatal necrosis and a complex dystonic movement disorder. Early diagnosis through newborn screening and adherence to metabolic treatment including lysine-restricted diet, carnitine supplementation, and emergency management during intercurrent illness can prevent striatal injury in the majority of patients. Even in treated cohorts, long-term surveillance is important, including attention to possible renal complications in adolescents and adults.

Ask OpenScientist

Ask a research question about Glutaryl-CoA Dehydrogenase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal recessive HP:0000007

Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance for biochemical phenotype but variable expressivity for neurological outcome. Carrier frequency varies by population.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:39185018 SUPPORT Human Clinical

"Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)"

Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.

◈

Mechanistic Hypotheses

Canonical GCDH Deficiency-Toxic Metabolite Model

canonical_ga1_metabolic_model CANONICAL

Biallelic GCDH loss of function impairs lysine catabolism, resulting in accumulation of neurotoxic metabolites (GA, 3-OH-GA, C5DC) that drive striatal injury and dystonia, particularly during catabolic stress.

Retained as CANONICAL with important scope qualifications. The 2026 falcon hypothesis-search report (kb/hypotheses/Glutaryl-CoA_Dehydrogenase_Deficiency/canonical_ga1_metabolic_model) confirmed the GCDH-loss-of-function → toxic-metabolite causal chain but identified three caveats: (1) low-excretor (LE) patients can develop classic basal ganglia injury with normal peripheral C5DC and absent urinary glutaric acid, indicating CNS metabolite trapping and/or local intracerebral production decouples peripheral biomarkers from brain risk; (2) astrocyte-mediated toxicity is a proximal effector (Gcdh-/- astrocytes are neurotoxic to striatal neurons via oxidative stress, while direct neuronal lysine/GA exposure is insufficient); (3) ~15-23% of treated patients still develop crises despite early NBS diagnosis and lysine-restricted diet, indicating the canonical chain is necessary but not sufficient. Causal reversal by neonatal AAV-GCDH gene therapy in mice provides the strongest interventional validation of the model.

Pathograph links

GCDH protein misfolding -> GCDH enzymatic deficiency and disrupted lysine catabolism DIRECT Loss of proper GCDH assembly decreases catalytic function in lysine degradation.

GCDH enzymatic deficiency and disrupted lysine catabolism -> Elevated glutarylcarnitine (C5DC) DIRECT GCDH deficiency produces elevated blood glutarylcarnitine, the primary acylcarnitine marker used for newborn screening.

GCDH enzymatic deficiency and disrupted lysine catabolism -> Elevated glutaric acid in urine DIRECT Impaired GCDH-dependent lysine catabolism causes urinary glutaric acid accumulation.

GCDH enzymatic deficiency and disrupted lysine catabolism -> Elevated 3-hydroxyglutaric acid in urine DIRECT Disrupted GCDH-dependent catabolism also elevates urinary 3-hydroxyglutaric acid, a diagnostic GA1 metabolite.

Brain exposure to toxic GA1 catabolites -> Macrocephaly INDIRECT UNKNOWN INTERMEDIATES The GA1 neurologic presentation often includes progressive macrocephaly in the same diagnostic context as characteristic brain MRI abnormalities.

Brain exposure to toxic GA1 catabolites -> Oxidative stress and neuroinflammation INDIRECT KNOWN INTERMEDIATES Toxic metabolite exposure perturbs redox balance and activates inflammatory pathways. Intermediates: mitochondrial dysfunction; lipid peroxidation; NF-kB pathway activation

Brain exposure to toxic GA1 catabolites -> Striatal vulnerability and encephalopathic crises DIRECT Toxic metabolite burden precipitates acute encephalopathy with selective striatal damage during stress.

Brain exposure to toxic GA1 catabolites -> Intellectual disability INDIRECT UNKNOWN INTERMEDIATES Chronic toxic-metabolite burden, especially the biochemical high-excreter state, is associated with cognitive impairment despite newborn-screening-era treatment.

Oxidative stress and neuroinflammation -> Striatal vulnerability and encephalopathic crises INDIRECT KNOWN INTERMEDIATES Redox and inflammatory injury amplify selective striatal degeneration. Intermediates: microglial activation; ER-mitochondria crosstalk disturbance; activated mitochondrial fission

Striatal vulnerability and encephalopathic crises -> Encephalopathy DIRECT Acute striatal degeneration manifests clinically as encephalopathic crises.

Striatal vulnerability and encephalopathic crises -> Hypotonia DIRECT Acute encephalopathic crises commonly include hypotonia as an early neurologic manifestation.

Striatal vulnerability and encephalopathic crises -> Motor delay INDIRECT UNKNOWN INTERMEDIATES Neurologic injury and infantile GA1 presentation are associated with loss of motor skills and frequent motor developmental delay.

Striatal vulnerability and encephalopathic crises -> Dystonia DIRECT Bilateral striatal injury produces chronic dystonic movement disorder.

Striatal vulnerability and encephalopathic crises -> Seizures DIRECT Seizures may occur as part of the acute encephalopathic crisis phenotype.

Striatal vulnerability and encephalopathic crises -> Frontotemporal cerebral atrophy INDIRECT KNOWN INTERMEDIATES Progressive striatal/cortical injury contributes to chronic cerebral atrophic changes. Intermediates: progressive cortical and striatal injury

Striatal vulnerability and encephalopathic crises -> Subdural hemorrhage INDIRECT KNOWN INTERMEDIATES Chronic cerebral atrophy and expanded CSF spaces in GA1 stretch cortical veins and predispose to subdural hematoma. Intermediates: cerebral atrophy and expansion of CSF spaces; stretching of cortical veins

Striatal vulnerability and encephalopathic crises -> Cerebral white matter hyperintensity on MRI INDIRECT KNOWN INTERMEDIATES White-matter microstructural injury accompanies gray-matter basal ganglia pathology. Intermediates: progressive cortical and striatal injury; white matter micropathologic damage

Deep research

Falcon citations 36 citations 2026-05-23T05:45:42.817249

Show evidence (4 references)

PMID:37685964 SUPPORT In Vitro

"Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency."

Establishes the canonical disease mechanism linking GCDH deficiency to neurotoxic metabolic pathology.

PMID:38983872 SUPPORT Model Organism

"AAV-GCDH significantly ameliorates the striatal neuropathology"

Neonatal systemic AAV-GCDH gene therapy in Gcdh KO mice prevents HLD-induced glutaric acid/3-OH-GA/C5DC accumulation in striatum and ameliorates striatal injury, gliosis, and myelination defects — the strongest interventional validation of the canonical enzyme-deficiency-to-striatal-injury causal chain.

PMID:25968119 PARTIAL In Vitro

"GCDH-defective astrocytes actively contribute to produce and accumulate GA and 3HGA when Lys catabolism is stressed"

Qualifies the canonical neuron-centric toxic-metabolite model: Gcdh-/- astrocytes synthesize/release GA and 3-OH-GA when challenged with lysine and mediate neurotoxicity. Direct neuronal exposure to lysine or GA without astrocytes is not toxic, identifying astrocytes as the proximal cellular effector of striatal neuronal death.

+ 1 more reference

Intracerebral Catabolite Origin Model

intracerebral_catabolite_origin_model ALTERNATIVE

Historical model proposing that toxic GA1 catabolites are generated predominantly within brain tissue and do not substantially cross the blood-brain barrier.

Pathograph links

GCDH enzymatic deficiency and disrupted lysine catabolism -> Brain exposure to toxic GA1 catabolites INDIRECT KNOWN INTERMEDIATES Historical model proposes predominant local production of toxic catabolites within the brain. Intermediates: local lysine catabolic flux in brain tissue; limited blood-brain barrier transport

Deep research

OpenScientist citations 27 citations 2026-05-23T04:05:10.575708

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier."

Captures the pre-existing local-production hypothesis as an alternative explanatory model.

Hepatic Catabolite Origin and Transport Model

hepatic_catabolite_origin_model EMERGING

Recent mouse data support predominant hepatic generation of toxic catabolites with subsequent transport to brain, revising prior assumptions of exclusively local brain production.

Pathograph links

GCDH enzymatic deficiency and disrupted lysine catabolism -> Brain exposure to toxic GA1 catabolites INDIRECT KNOWN INTERMEDIATES Alternative model proposes hepatic generation with transport of toxic catabolites to brain. Intermediates: hepatic lysine catabolic flux; systemic transport to the brain

Deep research

OpenScientist citations 25 citations 2026-05-23T04:17:54.058409

Show evidence (2 references)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Supports the liver-origin hypothesis as an emerging alternative to the intracerebral-origin model.

PMID:37075130 SUPPORT Model Organism

"Our findings question the current pathophysiological understanding of GA-1 and reveal a targeted therapy for this devastating disorder."

Indicates that newer data challenge the prior model and motivate updated mechanistic framing.

⚙

Pathophysiology

GCDH protein misfolding

Many GA1-causing missense variants lead to protein misfolding characterized by altered oligomerization, loss of protein stability and solubility, and increased susceptibility to aggregation. Reduced cellular activity is associated with loss of GCDH tetramerization. Variants closer to the N-terminus show more pronounced protein loss.

Canonical GCDH Deficiency-Toxic Metabolite Model

mitochondrial matrix link

Downstream

GCDH enzymatic deficiency and disrupted lysine catabolism Loss of proper GCDH assembly decreases catalytic function in lysine degradation.

Show evidence (3 references)

PMID:37685964 SUPPORT In Vitro

"An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed."

Comprehensive biochemical characterization of GCDH misfolding across multiple variants.

PMID:37685964 SUPPORT In Vitro

"The reduced cellular activity was associated with loss of tetramerization."

Loss of the native tetrameric assembly directly impairs enzymatic activity.

PMID:37685964 SUPPORT In Vitro

"The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder."

Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.

GCDH enzymatic deficiency and disrupted lysine catabolism

Deficiency of glutaryl-CoA dehydrogenase (GCDH), the last enzyme of lysine catabolism, drives accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC).

Canonical GCDH Deficiency-Toxic Metabolite Model Hepatic Catabolite Origin and Transport Model Intracerebral Catabolite Origin Model

cellular amino acid catabolic process link ↓ DECREASED proteinogenic amino acid catabolic process link ↓ DECREASED

glutaryl-CoA dehydrogenase activity link ↓ DECREASED

mitochondrial matrix link mitochondrion link

Liver link Striatum link

Downstream

Elevated glutarylcarnitine (C5DC) GCDH deficiency produces elevated blood glutarylcarnitine, the primary acylcarnitine marker used for newborn screening.

Elevated glutaric acid in urine Impaired GCDH-dependent lysine catabolism causes urinary glutaric acid accumulation.

Elevated 3-hydroxyglutaric acid in urine Disrupted GCDH-dependent catabolism also elevates urinary 3-hydroxyglutaric acid, a diagnostic GA1 metabolite.

Brain exposure to toxic GA1 catabolites Historical model proposes predominant local production of toxic catabolites within the brain.

Brain exposure to toxic GA1 catabolites Alternative model proposes hepatic generation with transport of toxic catabolites to brain.

Show evidence (2 references)

PMID:37075130 SUPPORT Model Organism

"Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism."

Defines GA1 as GCDH deficiency at the terminal step of lysine catabolism.

PMID:37685964 SUPPORT In Vitro

"Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency."

Supports the core enzymatic deficiency in GA1.

Brain exposure to toxic GA1 catabolites

Brain tissue exposure to GA, 3-OH-GA, and related metabolites is the convergent toxic step in GA1. Competing origin models (intracerebral production versus hepatic source with transport) can be superimposed at this node.

Canonical GCDH Deficiency-Toxic Metabolite Model Hepatic Catabolite Origin and Transport Model Intracerebral Catabolite Origin Model

Brain link Striatum link

Downstream

Macrocephaly The GA1 neurologic presentation often includes progressive macrocephaly in the same diagnostic context as characteristic brain MRI abnormalities.

Oxidative stress and neuroinflammation Toxic metabolite exposure perturbs redox balance and activates inflammatory pathways.

Striatal vulnerability and encephalopathic crises Toxic metabolite burden precipitates acute encephalopathy with selective striatal damage during stress.

Intellectual disability Chronic toxic-metabolite burden, especially the biochemical high-excreter state, is associated with cognitive impairment despite newborn-screening-era treatment.

Show evidence (2 references)

PMID:38983872 SUPPORT Model Organism

"a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites."

Supports toxic metabolite accumulation in brain as a proximal injury step.

PMID:37075130 SUPPORT Model Organism

"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches"

Rescue by liver-directed interventions supports metabolite burden as a causal brain-injury mediator.

Oxidative stress and neuroinflammation

GCDH deficiency leads to disturbed redox homeostasis including increased lipid peroxidation, altered antioxidant defenses, and a pro-inflammatory response in the striatum and cerebral cortex. NF-kB pathway activation and microglial activation contribute to neuroinflammation. Mitochondrial dynamics are also disrupted with activated mitochondrial fission.

Canonical GCDH Deficiency-Toxic Metabolite Model

Response to oxidative stress link Inflammatory response link

Striatum link Cerebral cortex link

Downstream

Striatal vulnerability and encephalopathic crises Redox and inflammatory injury amplify selective striatal degeneration.

Show evidence (2 references)

PMID:35639256 SUPPORT Model Organism

"Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex of Gcdh-/- mice."

Demonstrates oxidative stress in striatum and cortex of GCDH-deficient mice.

PMID:35639256 SUPPORT Model Organism

"the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response."

Shows NF-kB-mediated neuroinflammation in the striatum.

Striatal vulnerability and encephalopathic crises

The immature striatum is selectively vulnerable to damage during acute encephalopathic crises, typically occurring between ages 3 and 36 months. Catabolic stress from intercurrent illness triggers massive accumulation of neurotoxic metabolites, leading to bilateral striatal necrosis. This results in an irreversible complex dystonic movement disorder. The vulnerability window corresponds to a critical developmental period of striatal maturation.

Canonical GCDH Deficiency-Toxic Metabolite Model

Striatum link Putamen link Caudate nucleus link

Downstream

Encephalopathy Acute striatal degeneration manifests clinically as encephalopathic crises.

Hypotonia Acute encephalopathic crises commonly include hypotonia as an early neurologic manifestation.

Motor delay Neurologic injury and infantile GA1 presentation are associated with loss of motor skills and frequent motor developmental delay.

Dystonia Bilateral striatal injury produces chronic dystonic movement disorder.

Seizures Seizures may occur as part of the acute encephalopathic crisis phenotype.

Frontotemporal cerebral atrophy Progressive striatal/cortical injury contributes to chronic cerebral atrophic changes.

Subdural hemorrhage Chronic cerebral atrophy and expanded CSF spaces in GA1 stretch cortical veins and predispose to subdural hematoma.

Cerebral white matter hyperintensity on MRI White-matter microstructural injury accompanies gray-matter basal ganglia pathology.

Show evidence (3 references)

PMID:35639256 SUPPORT Model Organism

"commonly manifest acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury"

Confirms striatal degeneration as a hallmark of GA1 neuropathology.

PMID:37474264 SUPPORT Human Clinical

"The mean kurtosis values of the anterior and posterior putamen and Barry-Albright dystonia scores were most relevant (r = 0.721, 0.730, respectively)."

DKI imaging demonstrates that putamen microstructural damage correlates with dystonia severity.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"crises result in acute bilateral striatal injury and subsequent complex movement disorders."

GeneReviews summarizes the canonical striatal injury to movement-disorder progression in untreated GA1.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 1

Subdural hemorrhage OCCASIONAL Subdural hemorrhage (HP:0100309)

Show evidence (2 references)

PMID:26219480 SUPPORT Human Clinical

"Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces."

Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive head trauma.

PMID:26219480 SUPPORT Human Clinical

"SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1."

SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from abusive head trauma.

Head and Neck 1

Macrocephaly VERY_FREQUENT Macrocephaly (HP:0000256)

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"The most common clinical manifestations included increased head circumference (77.19%)"

Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.

Metabolism 1

Metabolic acidosis VERY_RARE Metabolic acidosis (HP:0001942)

GA1 differs from other organic acidurias in that encephalopathic crises are primarily neurological (striatal injury via excitotoxicity) rather than metabolic. Significant metabolic acidosis is uncommon.

Musculoskeletal 1

Hypotonia FREQUENT Hypotonia (HP:0001252)

Muscular hypotonia may be present in infancy as an early feature before the onset of dystonia. The Chinese literature review (PMID:39185018) identified motor developmental delay (65.15%) as the most common clinical manifestation, which often includes hypotonia in infants.

Nervous System 7

Dystonia FREQUENT Dystonia (HP:0001332)

Show evidence (1 reference)

PMID:37474264 SUPPORT Human Clinical

"The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores."

DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.

Motor delay VERY_FREQUENT Motor delay (HP:0001270)

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"motor developmental delay (65.15%)"

Literature review shows motor delay in 65% of GA1 patients.

Encephalopathy FREQUENT Encephalopathy (HP:0001298)

Show evidence (1 reference)

PMID:35639256 SUPPORT Model Organism

"commonly manifest acute encephalopathy associated with severe striatum degeneration"

Acute encephalopathy with striatal degeneration is the hallmark neurological event.

Seizures OCCASIONAL Seizure (HP:0001250)

Seizures may occur during or following acute encephalopathic crises. EEG abnormalities were documented in 73.33% of Chinese GA1 patients (PMID:39185018), but EEG abnormalities do not equate to clinical seizures. Post-crisis epilepsy is a recognized sequela of striatal injury.

Intellectual disability OCCASIONAL Intellectual disability (HP:0001249)

Show evidence (1 reference)

PMID:34588557 PARTIAL Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Cognitive impairment is documented, particularly in high excreters, but median IQ of 87 is below-average rather than meeting the threshold for intellectual disability (IQ <70). Most NBS-identified patients have mild cognitive effects rather than frank intellectual disability.

Frontotemporal cerebral atrophy FREQUENT Frontotemporal cerebral atrophy (HP:0006892)

Sequelae: Subdural hemorrhage

Show evidence (1 reference)

PMID:26219480 SUPPORT Human Clinical

"cerebral atrophy and expansion of CSF spaces"

Cerebral atrophy with CSF space expansion is a recognized GA1 neuroimaging feature.

Cerebral white matter hyperintensity on MRI FREQUENT Hyperintensity of cerebral white matter on MRI (HP:0030890)

Show evidence (1 reference)

PMID:37474264 SUPPORT Human Clinical

"Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores."

Supports white matter microstructural injury in GA1, consistent with MRI white matter abnormalities.

🧬

Genetic Associations

GCDH variants causing glutaryl-CoA dehydrogenase deficiency (CAUSATIVE)

Show evidence (4 references)

PMID:39185018 SUPPORT Human Clinical

"67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent type (73.97%). The most frequent variant was c.1244-2 A > C, observed in 17.12% of cases."

Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.

PMID:37685964 SUPPORT In Vitro

"The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype."

Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.

PMID:39185018 SUPPORT Human Clinical

"the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%)."

Identifies mutational hotspots in the GCDH gene.

+ 1 more reference

💊

Treatments

Lysine-restricted diet

Action: dietary intervention MAXO:0000088

A low-lysine or lysine-free diet is a cornerstone of GA1 metabolic treatment, aiming to reduce substrate availability for the deficient enzyme and decrease toxic metabolite production.

Mechanism Target:

INHIBITS Brain exposure to toxic GA1 catabolites — Lysine restriction reduces substrate flux intended to minimize CNS exposure to lysine-derived toxic byproducts.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

GeneReviews explicitly frames low-lysine diet as part of therapy aimed at minimizing CNS toxic-metabolite exposure.

Show evidence (2 references)

PMID:34588557 PARTIAL Human Clinical

"Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in high excreters.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.

Carnitine supplementation

Action: carnitine supplementation MAXO:0010006

Agent: carnitine ↗

L-carnitine supplementation helps replenish secondary carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC) and supports metabolite detoxification.

Mechanism Target:

MODULATES Brain exposure to toxic GA1 catabolites — Carnitine supplementation is part of combined metabolic therapy intended to reduce toxic byproduct exposure.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

GeneReviews includes carnitine supplementation in the combined regimen aimed at minimizing CNS toxic-metabolite exposure.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.

Emergency management during intercurrent illness

Action: supportive care MAXO:0000950

Aggressive emergency treatment during catabolic crises including high-energy intravenous glucose, prevention of catabolism, and monitoring to prevent acute striatal necrosis. The emergency protocol is critical during the vulnerability window (3-36 months of age).

Mechanism Target:

INHIBITS Striatal vulnerability and encephalopathic crises — Emergency illness management prevents catabolism during stressors that can precipitate striatal injury and encephalopathic crises.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

GeneReviews lists catabolic illness, fasting, and inadequate calories as circumstances to avoid, supporting emergency management as prevention of the crisis-triggering mechanism.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.

Newborn screening

Action: disease screening MAXO:0000124

Newborn screening (NBS) for GA1 using tandem mass spectrometry detection of elevated glutarylcarnitine (C5DC) enables presymptomatic diagnosis and early treatment initiation. Machine learning-based digital-tier strategies can reduce false-positive rates by over 90%.

Target Phenotypes: Encephalopathy ↗ Dystonia ↗

Show evidence (3 references)

PMID:39728403 SUPPORT Computational

"the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals with GA1 correctly."

Machine learning approaches can dramatically improve NBS specificity for GA1.

PMID:39185018 SUPPORT Human Clinical

"38.36% were diagnosed through newborn screening"

NBS is an important diagnostic route for GA1 in China.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Because the early initiation of treatment dramatically improved the outcome for persons with GA-1, an international guideline group has recommended NBS."

GeneReviews directly supports NBS as outcome-improving and guideline-recommended in GA1.

Genetic counseling

Action: genetic counseling MAXO:0000079

Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern, recurrence risk, and options for prenatal diagnosis.

Mechanism Target:

MODULATES GCDH enzymatic deficiency and disrupted lysine catabolism — Counseling addresses the autosomal recessive GCDH cause, recurrence risk, and family molecular testing rather than directly altering metabolism.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Once the GCDH pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."

GeneReviews ties genetic counseling actions to the familial GCDH pathogenic variants that define the proximal disease mechanism.

Show evidence (3 references)

PMID:39185018 SUPPORT Human Clinical

"These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling and prenatal diagnosis for their families."

Genetic variant identification enables genetic counseling and prenatal diagnosis.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Evaluation of relatives at risk: Testing of all at-risk sibs of any age to allow for early diagnosis and treatment."

GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

Confirms scope of reproductive and familial counseling options once familial variants are identified.

Gene therapy (investigational)

Action: gene therapy MAXO:0001001

AAV-mediated gene therapy is under preclinical investigation for GA1. Both liver-directed approaches (replacing GCDH or deleting AASS to prevent lysine degradation flux) and systemic AAV9-GCDH delivery have shown efficacy in mouse models, restoring enzyme activity and preventing lysine diet-induced neuropathology.

Mechanism Target:

RESTORES GCDH enzymatic deficiency and disrupted lysine catabolism — AAV-mediated GCDH replacement restores GCDH expression and enzyme activity in target tissues.

Show evidence (1 reference)

PMID:38983872 SUPPORT Model Organism

"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."

Supports restoration of the primary deficient enzymatic node by gene replacement therapy.

INHIBITS Brain exposure to toxic GA1 catabolites — Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches"

Supports inhibition of the downstream toxic-catabolite brain exposure pathway.

Show evidence (3 references)

PMID:37075130 SUPPORT Model Organism

"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the..."

Preclinical evidence for two liver-directed gene therapy strategies for GA1.

PMID:38983872 SUPPORT Model Organism

"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."

Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.

PMID:38983872 SUPPORT Model Organism

"AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination."

Gene therapy prevents striatal neuropathology in the GA1 mouse model.

Pharmacological chaperone therapy (investigational)

Action: Pharmacotherapy NCIT:C15986

Structure-targeted allosteric regulators are being explored as pharmacological chaperones for GA1 protein-misfolding variants, aiming to stabilize folded GCDH and increase residual enzyme function without competing with the natural substrate.

Mechanism Target:

MODULATES GCDH protein misfolding — Allosteric pharmacological chaperones are intended to stabilize folded GCDH protein and counter variant-associated misfolding.

Show evidence (1 reference)

PMID:39312412 SUPPORT In Vitro

"Allosteric regulators acting as pharmacological chaperones hold promise for innovative therapeutics since they target noncatalytic sites and stabilize the folded protein without competing with the natural substrate, resulting in a net gain of function."

The abstract describes the intended chaperone mechanism as stabilization of folded protein with gain of function.

Show evidence (1 reference)

PMID:39312412 SUPPORT In Vitro

"Putative allosteric regulators were discovered using structure- and ligand-based virtual screening methods and validated using orthogonal biophysical and biochemical assays."

Preclinical computational discovery followed by biochemical/biophysical validation supports investigational chaperone pharmacotherapy for GA1.

Bezafibrate (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: bezafibrate ↗

The pan-PPAR agonist bezafibrate has shown neuroprotective effects in GCDH-deficient mice by normalizing oxidative stress and neuroinflammation in the striatum.

Mechanism Target:

INHIBITS Oxidative stress and neuroinflammation — Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.

Show evidence (1 reference)

PMID:35639256 SUPPORT Model Organism

"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."

Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.

Show evidence (2 references)

PMID:35639256 SUPPORT Model Organism

"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."

Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.

PMID:35639256 SUPPORT Model Organism

"bezafibrate should be tested as a potential adjuvant therapy for GA1."

Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.

🔬

Biochemical Markers

Elevated glutarylcarnitine (C5DC) (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency and disrupted lysine catabolism Positive Diagnostic

Elevated C5DC in blood reports the disrupted GCDH-dependent lysine-catabolism pathway.

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood"

C5DC elevation in blood is near-universal in GA1 patients.

Elevated glutaric acid in urine (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency and disrupted lysine catabolism Positive Diagnostic

Urinary glutaric acid elevation reports accumulation of GA1 catabolites downstream of GCDH deficiency.

Show evidence (2 references)

PMID:39185018 SUPPORT Human Clinical

"GA (94.37%) and 3OHGA (69.39%) in urine"

Urinary GA elevation is present in the vast majority of GA1 patients.

PMID:34588557 SUPPORT Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment"

The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.

Elevated 3-hydroxyglutaric acid in urine (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency and disrupted lysine catabolism Positive Diagnostic

Urinary 3-OH-GA elevation reports accumulation of neurotoxic GA1 metabolites downstream of GCDH deficiency.

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"GA (94.37%) and 3OHGA (69.39%) in urine"

Urinary 3-OH-GA elevation is present in about 69% of GA1 patients.

{ }

Source YAML

click to show

name: Glutaryl-CoA Dehydrogenase Deficiency
creation_date: '2025-12-15T00:00:00Z'
updated_date: '2026-05-21T01:11:47Z'
category: Mendelian
description: 'Glutaryl-CoA dehydrogenase deficiency (historically termed glutaric aciduria type 1, GA1) is a rare autosomal recessive neurometabolic disorder caused by deficiency of glutaryl-CoA dehydrogenase (GCDH), which catalyzes the final step of lysine, hydroxylysine, and tryptophan catabolism. GCDH deficiency leads to accumulation of neurotoxic metabolites glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC). Untreated disease ranges from infantile-onset to later-onset forms (after age six years). Affected individuals are at highest risk for acute encephalopathic crises in early childhood (especially ages 3-36 months), often triggered by catabolic stress, which cause irreversible bilateral striatal necrosis and a complex dystonic movement disorder. Early diagnosis through newborn screening and adherence to metabolic treatment including lysine-restricted diet, carnitine supplementation, and emergency management during intercurrent illness can prevent striatal injury in the majority of patients. Even in treated cohorts, long-term surveillance is important, including attention to possible renal complications in adolescents and adults.

  '
disease_term:
  preferred_term: glutaryl-CoA dehydrogenase deficiency
  term:
    id: MONDO:0009281
    label: glutaryl-CoA dehydrogenase deficiency
synonyms:
- glutaric aciduria type 1
- glutaric acidemia type 1
- GA1
parents:
- Organic Acidemia
- Inborn Error of Metabolism
references:
- reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
  title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
  findings:
  - statement: NBS-identified and promptly treated individuals often avoid classic early striatal injury but still need long-term follow-up.
    supporting_text: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
      explanation: Supports continued surveillance, including renal monitoring, despite prevention of classic early neurologic crises.
  - statement: Standard care is combined metabolic therapy centered on lysine restriction, carnitine supplementation, and emergency illness management.
    supporting_text: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: Captures core treatment principles that structure current management recommendations.
  - statement: Catabolic triggers should be proactively avoided in GA1 management plans.
    supporting_text: "Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
      explanation: Provides explicit avoidant-trigger guidance for sick-day and peri-procedural planning.
- reference: DOI:10.1002/jimd.12608
  title: Exploring genotype–phenotype correlations in glutaric aciduria type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
    supporting_text: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
    evidence:
    - reference: DOI:10.1002/jimd.12608
      reference_title: Exploring genotype–phenotype correlations in glutaric aciduria type 1
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1007/s10545-011-9289-5
  title: Diagnosis and management of glutaric aciduria type I – revised recommendations
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
    supporting_text: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
    evidence:
    - reference: DOI:10.1007/s10545-011-9289-5
      reference_title: Diagnosis and management of glutaric aciduria type I – revised recommendations
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1021/acs.jmedchem.4c00292
  title: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
    supporting_text: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
- reference: DOI:10.11588/heidok.00035789
  title: New approaches in mathematical and data-based modeling for newborn screening
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: New approaches in mathematical and data-based modeling for newborn screening
    supporting_text: New approaches in mathematical and data-based modeling for newborn screening
- reference: DOI:10.1186/s13023-023-02833-z
  title: Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
    supporting_text: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
    evidence:
    - reference: DOI:10.1186/s13023-023-02833-z
      reference_title: Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1186/s13052-025-01975-z
  title: 'Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
    supporting_text: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
    evidence:
    - reference: DOI:10.1186/s13052-025-01975-z
      reference_title: 'Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.7759/cureus.65722
  title: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
    supporting_text: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
- reference: DOI:10.7759/cureus.86380
  title: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
    supporting_text: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
- reference: DOI:10.1016/j.omtm.2024.101276
  title: Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms241713158
  title: Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijns10040083
  title: Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: 'Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance for biochemical phenotype but variable expressivity for neurological outcome. Carrier frequency varies by population.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)
    explanation: Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
    explanation: GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.
prevalence:
- population: Black South African newborns
  percentage: 1 in 5,184
  notes: >-
    This founder population estimate is substantially higher than the low
    prevalence usually described for GA1 in Europe and other outbred
    populations.
  evidence:
  - reference: PMID:20732827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygosity for the A293T mutation was found 1 in 36 (95% CI; 1/54 - 1/24) unrelated black South African newborns (n=750) giving a predicted prevalence rate for GA 1 of 1 in 5184 (95% CI; 1/11664 - 1/2304) in this population."
    explanation: Newborn carrier screening and founder-mutation analysis provide a quantitative prevalence estimate for this high-risk population.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_ga1_metabolic_model
  hypothesis_label: Canonical GCDH Deficiency-Toxic Metabolite Model
  status: CANONICAL
  description: >-
    Biallelic GCDH loss of function impairs lysine catabolism, resulting in accumulation
    of neurotoxic
    metabolites (GA, 3-OH-GA, C5DC) that drive striatal injury and dystonia, particularly
    during catabolic stress.
  notes: >-
    Retained as CANONICAL with important scope qualifications. The 2026
    falcon hypothesis-search report
    (kb/hypotheses/Glutaryl-CoA_Dehydrogenase_Deficiency/canonical_ga1_metabolic_model)
    confirmed the GCDH-loss-of-function → toxic-metabolite causal chain
    but identified three caveats: (1) low-excretor (LE) patients can
    develop classic basal ganglia injury with normal peripheral C5DC and
    absent urinary glutaric acid, indicating CNS metabolite trapping
    and/or local intracerebral production decouples peripheral biomarkers
    from brain risk; (2) astrocyte-mediated toxicity is a proximal
    effector (Gcdh-/- astrocytes are neurotoxic to striatal neurons via
    oxidative stress, while direct neuronal lysine/GA exposure is
    insufficient); (3) ~15-23% of treated patients still develop crises
    despite early NBS diagnosis and lysine-restricted diet, indicating
    the canonical chain is necessary but not sufficient. Causal reversal
    by neonatal AAV-GCDH gene therapy in mice provides the strongest
    interventional validation of the model.
  evidence:
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency.
    explanation: Establishes the canonical disease mechanism linking GCDH deficiency to neurotoxic metabolic pathology.
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "AAV-GCDH significantly ameliorates the striatal neuropathology"
    explanation: >
      Neonatal systemic AAV-GCDH gene therapy in Gcdh KO mice prevents
      HLD-induced glutaric acid/3-OH-GA/C5DC accumulation in striatum and
      ameliorates striatal injury, gliosis, and myelination defects —
      the strongest interventional validation of the canonical
      enzyme-deficiency-to-striatal-injury causal chain.
  - reference: PMID:25968119
    reference_title: "Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "GCDH-defective astrocytes actively contribute to produce and accumulate GA and 3HGA when Lys catabolism is stressed"
    explanation: >
      Qualifies the canonical neuron-centric toxic-metabolite model:
      Gcdh-/- astrocytes synthesize/release GA and 3-OH-GA when challenged
      with lysine and mediate neurotoxicity. Direct neuronal exposure to
      lysine or GA without astrocytes is not toxic, identifying astrocytes
      as the proximal cellular effector of striatal neuronal death.
  - reference: PMID:20923787
    reference_title: "Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the pipecolate pathway is the major route of L-lysine degradation in the brain and the saccharopine pathway is the major route in the liver"
    explanation: >
      Substrate-flux reduction in Gcdh-/- mice via low-lysine diet
      reduces GA across tissues; L-arginine amplifies the effect through
      BBB transporter competition. The dual hepatic-saccharopine /
      cerebral-pipecolate routes also explain incomplete normalization
      with single-pathway interventions, identifying cerebral lysine
      metabolism as a therapeutic target central to the canonical
      mechanism.
- hypothesis_group_id: intracerebral_catabolite_origin_model
  hypothesis_label: Intracerebral Catabolite Origin Model
  status: ALTERNATIVE
  description: >-
    Historical model proposing that toxic GA1 catabolites are generated predominantly
    within brain tissue
    and do not substantially cross the blood-brain barrier.
  evidence:
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier.
    explanation: Captures the pre-existing local-production hypothesis as an alternative explanatory model.
- hypothesis_group_id: hepatic_catabolite_origin_model
  hypothesis_label: Hepatic Catabolite Origin and Transport Model
  status: EMERGING
  description: >-
    Recent mouse data support predominant hepatic generation of toxic catabolites
    with subsequent transport to brain,
    revising prior assumptions of exclusively local brain production.
  evidence:
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
    explanation: Supports the liver-origin hypothesis as an emerging alternative to the intracerebral-origin model.
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Our findings question the current pathophysiological understanding of GA-1 and reveal a targeted therapy for this devastating disorder.
    explanation: Indicates that newer data challenge the prior model and motivate updated mechanistic framing.
pathophysiology:
- name: GCDH protein misfolding
  description: 'Many GA1-causing missense variants lead to protein misfolding characterized by altered oligomerization, loss of protein stability and solubility, and increased susceptibility to aggregation. Reduced cellular activity is associated with loss of GCDH tetramerization. Variants closer to the N-terminus show more pronounced protein loss.

    '
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, whose missense variants lead to protein misfolding and loss of enzymatic activity.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed.
    explanation: Comprehensive biochemical characterization of GCDH misfolding across multiple variants.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The reduced cellular activity was associated with loss of tetramerization.
    explanation: Loss of the native tetrameric assembly directly impairs enzymatic activity.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder.
    explanation: Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.
  downstream:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    description: Loss of proper GCDH assembly decreases catalytic function in lysine degradation.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37685964
      reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The reduced cellular activity was associated with loss of tetramerization.
      explanation: Links variant-driven misfolding directly to reduced enzymatic function.
- name: GCDH enzymatic deficiency and disrupted lysine catabolism
  description: >-
    Deficiency of glutaryl-CoA dehydrogenase (GCDH), the last enzyme of lysine catabolism,
    drives accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and
    glutarylcarnitine (C5DC).
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, a mitochondrial matrix enzyme catalyzing oxidative decarboxylation of glutaryl-CoA.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  molecular_functions:
  - preferred_term: glutaryl-CoA dehydrogenase activity
    term:
      id: GO:0004361
      label: glutaryl-CoA dehydrogenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: cellular amino acid catabolic process
    term:
      id: GO:0009063
      label: amino acid catabolic process
    modifier: DECREASED
  - preferred_term: proteinogenic amino acid catabolic process
    term:
      id: GO:0170040
      label: proteinogenic amino acid catabolic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: glutaric acid
    term:
      id: CHEBI:17859
      label: glutaric acid
    modifier: INCREASED
  - preferred_term: 3-hydroxyglutaric acid
    term:
      id: CHEBI:39980
      label: 3-hydroxyglutaric acid
    modifier: INCREASED
  - preferred_term: glutarylcarnitine
    term:
      id: CHEBI:82952
      label: O-glutaroyl-L-carnitine
    modifier: INCREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: Liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism.
    explanation: Defines GA1 as GCDH deficiency at the terminal step of lysine catabolism.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency.
    explanation: Supports the core enzymatic deficiency in GA1.
  downstream:
  - target: Elevated glutarylcarnitine (C5DC)
    description: GCDH deficiency produces elevated blood glutarylcarnitine, the primary acylcarnitine marker used for newborn screening.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39185018
      reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood
      explanation: Human cohort/literature-review data support C5DC as a high-frequency biochemical consequence of GCDH deficiency.
  - target: Elevated glutaric acid in urine
    description: Impaired GCDH-dependent lysine catabolism causes urinary glutaric acid accumulation.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39185018
      reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: GA (94.37%) and 3OHGA (69.39%) in urine
      explanation: Human cohort/literature-review data support urinary glutaric acid as a frequent biochemical consequence of GA1.
  - target: Elevated 3-hydroxyglutaric acid in urine
    description: Disrupted GCDH-dependent catabolism also elevates urinary 3-hydroxyglutaric acid, a diagnostic GA1 metabolite.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39185018
      reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: GA (94.37%) and 3OHGA (69.39%) in urine
      explanation: Human cohort/literature-review data support urinary 3-hydroxyglutaric acid as a frequent biochemical consequence of GA1.
  - target: Brain exposure to toxic GA1 catabolites
    description: Historical model proposes predominant local production of toxic catabolites within the brain.
    hypothesis_groups:
    - intracerebral_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - local lysine catabolic flux in brain tissue
    - limited blood-brain barrier transport
    evidence:
    - reference: PMID:37075130
      reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier.
      explanation: Encodes the prior intracerebral-origin hypothesis as one possible edge.
  - target: Brain exposure to toxic GA1 catabolites
    description: Alternative model proposes hepatic generation with transport of toxic catabolites to brain.
    hypothesis_groups:
    - hepatic_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - hepatic lysine catabolic flux
    - systemic transport to the brain
    evidence:
    - reference: PMID:37075130
      reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
      explanation: Encodes the liver-origin hypothesis as an alternative edge to the same downstream node.
- name: Brain exposure to toxic GA1 catabolites
  description: >-
    Brain tissue exposure to GA, 3-OH-GA, and related metabolites is the convergent
    toxic step in GA1.
    Competing origin models (intracerebral production versus hepatic source with transport)
    can be superimposed at this node.
  locations:
  - preferred_term: Brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites.
    explanation: Supports toxic metabolite accumulation in brain as a proximal injury step.
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches
    explanation: Rescue by liver-directed interventions supports metabolite burden as a causal brain-injury mediator.
  downstream:
  - target: Macrocephaly
    description: The GA1 neurologic presentation often includes progressive macrocephaly in the same diagnostic context as characteristic brain MRI abnormalities.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Progressive macrocephaly is observed in 75% of affected individuals and may be present prenatally
      explanation: GeneReviews supports macrocephaly as a frequent neurologic manifestation in GA1; the exact causal intermediate is not specified.
  - target: Oxidative stress and neuroinflammation
    description: Toxic metabolite exposure perturbs redox balance and activates inflammatory pathways.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    - intracerebral_catabolite_origin_model
    - hepatic_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial dysfunction
    - lipid peroxidation
    - NF-kB pathway activation
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex of Gcdh-/- mice.
      explanation: Supports transition from metabolite burden to oxidative and inflammatory injury.
  - target: Striatal vulnerability and encephalopathic crises
    description: Toxic metabolite burden precipitates acute encephalopathy with selective striatal damage during stress.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    - intracerebral_catabolite_origin_model
    - hepatic_catabolite_origin_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury
      explanation: Directly links brain metabolite toxicity to encephalopathy and striatal degeneration.
  - target: Intellectual disability
    description: Chronic toxic-metabolite burden, especially the biochemical high-excreter state, is associated with cognitive impairment despite newborn-screening-era treatment.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34588557
      reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
      explanation: Prospective human follow-up links the high-excreter biochemical state to cognitive impairment; the phenotype entry remains cautious because most patients show mild cognitive effects rather than frank intellectual disability.
- name: Oxidative stress and neuroinflammation
  description: 'GCDH deficiency leads to disturbed redox homeostasis including increased lipid peroxidation, altered antioxidant defenses, and a pro-inflammatory response in the striatum and cerebral cortex. NF-kB pathway activation and microglial activation contribute to neuroinflammation. Mitochondrial dynamics are also disrupted with activated mitochondrial fission.

    '
  biological_processes:
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: Cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex of Gcdh-/- mice.
    explanation: Demonstrates oxidative stress in striatum and cortex of GCDH-deficient mice.
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response.
    explanation: Shows NF-kB-mediated neuroinflammation in the striatum.
  downstream:
  - target: Striatal vulnerability and encephalopathic crises
    description: Redox and inflammatory injury amplify selective striatal degeneration.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - microglial activation
    - ER-mitochondria crosstalk disturbance
    - activated mitochondrial fission
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We presume that some of these novel pathomechanisms may be involved in GA1 neuropathology
      explanation: Supports oxidative and inflammatory pathomechanisms as amplifiers of neuropathology.
- name: Striatal vulnerability and encephalopathic crises
  description: 'The immature striatum is selectively vulnerable to damage during acute encephalopathic crises, typically occurring between ages 3 and 36 months. Catabolic stress from intercurrent illness triggers massive accumulation of neurotoxic metabolites, leading to bilateral striatal necrosis. This results in an irreversible complex dystonic movement disorder. The vulnerability window corresponds to a critical developmental period of striatal maturation.

    '
  locations:
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: Putamen
    term:
      id: UBERON:0001874
      label: putamen
  - preferred_term: Caudate nucleus
    term:
      id: UBERON:0001873
      label: caudate nucleus
  evidence:
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: commonly manifest acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury
    explanation: Confirms striatal degeneration as a hallmark of GA1 neuropathology.
  - reference: PMID:37474264
    reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean kurtosis values of the anterior and posterior putamen and Barry-Albright dystonia scores were most relevant (r = 0.721, 0.730, respectively).
    explanation: DKI imaging demonstrates that putamen microstructural damage correlates with dystonia severity.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: crises result in acute bilateral striatal injury and subsequent complex movement disorders.
    explanation: GeneReviews summarizes the canonical striatal injury to movement-disorder progression in untreated GA1.
  downstream:
  - target: Encephalopathy
    description: Acute striatal degeneration manifests clinically as encephalopathic crises.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury
      explanation: Supports acute encephalopathy as the clinical expression of severe striatal degeneration in the GA1 model.
  - target: Hypotonia
    description: Acute encephalopathic crises commonly include hypotonia as an early neurologic manifestation.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: acute encephalopathic crisis (hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures)
      explanation: GeneReviews explicitly lists hypotonia as part of the acute encephalopathic crisis presentation.
  - target: Motor delay
    description: Neurologic injury and infantile GA1 presentation are associated with loss of motor skills and frequent motor developmental delay.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39185018
      reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The most common clinical manifestations included increased head circumference (77.19%) and motor developmental delay (65.15%).
      explanation: Human literature-review data support motor developmental delay as a common downstream clinical manifestation in GA1.
  - target: Dystonia
    description: Bilateral striatal injury produces chronic dystonic movement disorder.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37474264
      reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores.
      explanation: Supports a direct striatal injury to dystonia relationship.
  - target: Seizures
    description: Seizures may occur as part of the acute encephalopathic crisis phenotype.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: acute encephalopathic crisis (hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures)
      explanation: GeneReviews explicitly lists seizures as an occasional manifestation during acute encephalopathic crises.
  - target: Frontotemporal cerebral atrophy
    description: Progressive striatal/cortical injury contributes to chronic cerebral atrophic changes.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive cortical and striatal injury
    evidence:
    - reference: PMID:26219480
      reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: cerebral atrophy and expansion of CSF spaces
      explanation: Supports downstream cerebral atrophy after recurrent neurotoxic injury.
  - target: Subdural hemorrhage
    description: Chronic cerebral atrophy and expanded CSF spaces in GA1 stretch cortical veins and predispose to subdural hematoma.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebral atrophy and expansion of CSF spaces
    - stretching of cortical veins
    evidence:
    - reference: PMID:26219480
      reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
      explanation: Systematic review evidence links GA1-associated cerebral atrophy and expanded CSF spaces to subdural hematoma predisposition.
  - target: Cerebral white matter hyperintensity on MRI
    description: White-matter microstructural injury accompanies gray-matter basal ganglia pathology.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive cortical and striatal injury
    - white matter micropathologic damage
    evidence:
    - reference: PMID:37474264
      reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores.
      explanation: Supports white matter injury as a downstream neuroimaging consequence.
phenotypes:
- name: Macrocephaly
  frequency: VERY_FREQUENT
  description: 'Increased head circumference is one of the most common clinical manifestations, present in approximately 77% of patients. Often the first clinical sign raising suspicion before screening results are available.

    '
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical manifestations included increased head circumference (77.19%)
    explanation: Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.
- name: Dystonia
  frequency: FREQUENT
  description: 'Complex dystonic movement disorder resulting from bilateral striatal injury during encephalopathic crises. Severity correlates with extent of putamen damage on neuroimaging.

    '
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:37474264
    reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores.
    explanation: DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.
- name: Motor delay
  frequency: VERY_FREQUENT
  description: 'Developmental motor delay is common, present in approximately 65% of patients. May be evident before or after an encephalopathic crisis.

    '
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: motor developmental delay (65.15%)
    explanation: Literature review shows motor delay in 65% of GA1 patients.
- name: Encephalopathy
  frequency: FREQUENT
  description: 'Acute encephalopathic crises typically occur between 3 and 36 months of age, often triggered by catabolic stress from febrile illness. These crises cause irreversible striatal injury if not prevented by emergency management.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: commonly manifest acute encephalopathy associated with severe striatum degeneration
    explanation: Acute encephalopathy with striatal degeneration is the hallmark neurological event.
- name: Subdural hemorrhage
  frequency: OCCASIONAL
  description: 'Children with GA1 are predisposed to subdural hematoma development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces. SDH in GA1 must be distinguished from abusive head trauma.

    '
  phenotype_term:
    preferred_term: Subdural hemorrhage
    term:
      id: HP:0100309
      label: Subdural hemorrhage
  evidence:
  - reference: PMID:26219480
    reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
    explanation: Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive head trauma.
  - reference: PMID:26219480
    reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1.
    explanation: SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from abusive head trauma.
- name: Metabolic acidosis
  frequency: VERY_RARE
  description: >-
    Unlike other organic acidurias (e.g., propionic acidemia, methylmalonic acidemia),
    GA1 does not
    characteristically cause significant metabolic acidosis. Encephalopathic crises
    in GA1 are primarily
    neurological events (striatal necrosis) rather than metabolic acidosis episodes.
    Metabolic acidosis
    may occur rarely during severe intercurrent illness but is not a defining feature.
  phenotype_term:
    preferred_term: Metabolic acidosis
    term:
      id: HP:0001942
      label: Metabolic acidosis
  notes: >-
    GA1 differs from other organic acidurias in that encephalopathic crises are primarily
    neurological
    (striatal injury via excitotoxicity) rather than metabolic. Significant metabolic
    acidosis is uncommon.
- name: Seizures
  frequency: OCCASIONAL
  description: Seizures may occur during or after encephalopathic crises.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: >-
    Seizures may occur during or following acute encephalopathic crises. EEG abnormalities
    were documented
    in 73.33% of Chinese GA1 patients (PMID:39185018), but EEG abnormalities do not
    equate to clinical
    seizures. Post-crisis epilepsy is a recognized sequela of striatal injury.
- name: Intellectual disability
  frequency: OCCASIONAL
  description: >-
    Cognitive performance is mildly reduced in GA1 patients identified by newborn
    screening, particularly
    in those with the biochemical high excreter phenotype (median IQ 84) compared
    to low excreters
    (median IQ 98). Most patients do not meet criteria for intellectual disability
    (IQ <70) but
    have below-average cognitive function.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34588557
    reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
    explanation: Cognitive impairment is documented, particularly in high excreters, but median IQ of 87 is below-average rather than meeting the threshold for intellectual disability (IQ <70). Most NBS-identified patients have mild cognitive effects rather than frank intellectual disability.
- name: Hypotonia
  frequency: FREQUENT
  description: 'Muscular hypotonia may be present in infancy, particularly before the onset of dystonia.

    '
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  notes: >-
    Muscular hypotonia may be present in infancy as an early feature before the onset
    of dystonia.
    The Chinese literature review (PMID:39185018) identified motor developmental delay
    (65.15%)
    as the most common clinical manifestation, which often includes hypotonia in infants.
- name: Frontotemporal cerebral atrophy
  frequency: FREQUENT
  description: 'Frontotemporal atrophy with widened Sylvian fissures and expanded CSF spaces is a characteristic neuroimaging finding in GA1.

    '
  phenotype_term:
    preferred_term: Frontotemporal cerebral atrophy
    term:
      id: HP:0006892
      label: Frontotemporal cerebral atrophy
  evidence:
  - reference: PMID:26219480
    reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cerebral atrophy and expansion of CSF spaces
    explanation: Cerebral atrophy with CSF space expansion is a recognized GA1 neuroimaging feature.
  sequelae:
  - target: Subdural hemorrhage
    description: Cerebral atrophy and expanded CSF spaces stretch cortical veins and predispose to subdural hematoma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26219480
      reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
      explanation: Directly links the GA1 cerebral atrophy/expanded-CSF phenotype to subdural hematoma predisposition.
- name: Cerebral white matter hyperintensity on MRI
  frequency: FREQUENT
  description: 'Abnormalities in white matter are detected on MRI in the majority of GA1 patients.

    '
  phenotype_term:
    preferred_term: Hyperintensity of cerebral white matter on MRI
    term:
      id: HP:0030890
      label: Hyperintensity of cerebral white matter on MRI
  evidence:
  - reference: PMID:37474264
    reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores.
    explanation: Supports white matter microstructural injury in GA1, consistent with MRI white matter abnormalities.
biochemical:
- name: Elevated glutarylcarnitine (C5DC)
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated C5DC in blood reports the disrupted GCDH-dependent lysine-catabolism pathway.
  notes: 'C5DC is the primary newborn screening biomarker for GA1 detected by tandem mass spectrometry. Elevated in blood in approximately 98.5% of GA1 patients.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood
    explanation: C5DC elevation in blood is near-universal in GA1 patients.
- name: Elevated glutaric acid in urine
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary glutaric acid elevation reports accumulation of GA1 catabolites downstream of GCDH deficiency.
  notes: 'Glutaric acid is elevated in urine in approximately 94% of GA1 patients. The level of urinary GA excretion distinguishes high excreters from low excreters.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Urinary GA elevation is present in the vast majority of GA1 patients.
  - reference: PMID:34588557
    reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment
    explanation: The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.
- name: Elevated 3-hydroxyglutaric acid in urine
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary 3-OH-GA elevation reports accumulation of neurotoxic GA1 metabolites downstream of GCDH deficiency.
  notes: '3-OH-GA is elevated in urine in approximately 69% of GA1 patients and is considered the most neurotoxic metabolite.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Urinary 3-OH-GA elevation is present in about 69% of GA1 patients.
genetic:
- name: GCDH variants causing glutaryl-CoA dehydrogenase deficiency
  gene_term:
    preferred_term: GCDH
    term:
      id: hgnc:4189
      label: GCDH
  association: CAUSATIVE
  features: 'Biallelic pathogenic variants in the GCDH gene cause GA1. Over 200 pathogenic variants have been identified. Missense variants are the most prevalent type (approximately 74%). The most frequent variant in Chinese populations is c.1244-2A>C. Most variant sites are located in exons 11 and 6. Genotype-phenotype correlations exist, with some variants associated with residual GCDH activity and the low excreter biochemical phenotype.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent type (73.97%). The most frequent variant was c.1244-2 A > C, observed in 17.12% of cases.
    explanation: Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype.
    explanation: Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%).
    explanation: Identifies mutational hotspots in the GCDH gene.
  - reference: CGGV:assertion_33a2c95e-a057-4b93-b97e-27b6597516e5-2019-11-08T170000.000Z
    reference_title: "GCDH / glutaryl-CoA dehydrogenase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GCDH | HGNC:4189 | glutaryl-CoA dehydrogenase deficiency | MONDO:0009281 | AR | Definitive"
    explanation: ClinGen classifies the GCDH-glutaryl-CoA dehydrogenase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Lysine-restricted diet
  description: 'A low-lysine or lysine-free diet is a cornerstone of GA1 metabolic treatment, aiming to reduce substrate availability for the deficient enzyme and decrease toxic metabolite production.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Brain exposure to toxic GA1 catabolites
    treatment_effect: INHIBITS
    description: Lysine restriction reduces substrate flux intended to minimize CNS exposure to lysine-derived toxic byproducts.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: GeneReviews explicitly frames low-lysine diet as part of therapy aimed at minimizing CNS toxic-metabolite exposure.
  evidence:
  - reference: PMID:34588557
    reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
    explanation: Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in high excreters.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.
- name: Carnitine supplementation
  description: 'L-carnitine supplementation helps replenish secondary carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC) and supports metabolite detoxification.

    '
  treatment_term:
    preferred_term: carnitine supplementation
    term:
      id: MAXO:0010006
      label: carnitine supplementation
    therapeutic_agent:
    - preferred_term: carnitine
      term:
        id: CHEBI:17126
        label: carnitine
  target_mechanisms:
  - target: Brain exposure to toxic GA1 catabolites
    treatment_effect: MODULATES
    description: Carnitine supplementation is part of combined metabolic therapy intended to reduce toxic byproduct exposure.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: GeneReviews includes carnitine supplementation in the combined regimen aimed at minimizing CNS toxic-metabolite exposure.
  notes: >-
    L-carnitine supplementation is recommended in international GA1 guidelines to
    replenish secondary
    carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC). Nearly
    all GA1 patients
    (98.51%) show elevated C5DC (PMID:39185018), reflecting ongoing carnitine conjugation
    and loss.
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.
- name: Emergency management during intercurrent illness
  description: 'Aggressive emergency treatment during catabolic crises including high-energy intravenous glucose, prevention of catabolism, and monitoring to prevent acute striatal necrosis. The emergency protocol is critical during the vulnerability window (3-36 months of age).

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_mechanisms:
  - target: Striatal vulnerability and encephalopathic crises
    treatment_effect: INHIBITS
    description: Emergency illness management prevents catabolism during stressors that can precipitate striatal injury and encephalopathic crises.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
      explanation: GeneReviews lists catabolic illness, fasting, and inadequate calories as circumstances to avoid, supporting emergency management as prevention of the crisis-triggering mechanism.
  notes: >-
    Aggressive emergency treatment during catabolic crises is a cornerstone of GA1
    management per
    international guidelines. The German NBS follow-up cohort (PMID:34588557, n=107)
    demonstrates that
    early identification and treatment adherence are critical for outcomes.
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
    explanation: Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.
- name: Newborn screening
  description: 'Newborn screening (NBS) for GA1 using tandem mass spectrometry detection of elevated glutarylcarnitine (C5DC) enables presymptomatic diagnosis and early treatment initiation. Machine learning-based digital-tier strategies can reduce false-positive rates by over 90%.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  target_phenotypes:
  - preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:39728403
    reference_title: "Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals with GA1 correctly.
    explanation: Machine learning approaches can dramatically improve NBS specificity for GA1.
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 38.36% were diagnosed through newborn screening
    explanation: NBS is an important diagnostic route for GA1 in China.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Because the early initiation of treatment dramatically improved the outcome for persons with GA-1, an international guideline group has recommended NBS.
    explanation: GeneReviews directly supports NBS as outcome-improving and guideline-recommended in GA1.
- name: Genetic counseling
  description: 'Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern, recurrence risk, and options for prenatal diagnosis.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  target_mechanisms:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    treatment_effect: MODULATES
    description: Counseling addresses the autosomal recessive GCDH cause, recurrence risk, and family molecular testing rather than directly altering metabolism.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Once the <i>GCDH</i> pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
      explanation: GeneReviews ties genetic counseling actions to the familial GCDH pathogenic variants that define the proximal disease mechanism.
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling and prenatal diagnosis for their families.
    explanation: Genetic variant identification enables genetic counseling and prenatal diagnosis.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<i>Evaluation of relatives at risk:</i> Testing of all at-risk sibs of any age to allow for early diagnosis and treatment."
    explanation: GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Once the <i>GCDH</i> pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
    explanation: Confirms scope of reproductive and familial counseling options once familial variants are identified.
- name: Gene therapy (investigational)
  description: 'AAV-mediated gene therapy is under preclinical investigation for GA1. Both liver-directed approaches (replacing GCDH or deleting AASS to prevent lysine degradation flux) and systemic AAV9-GCDH delivery have shown efficacy in mouse models, restoring enzyme activity and preventing lysine diet-induced neuropathology.

    '
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    treatment_effect: RESTORES
    description: AAV-mediated GCDH replacement restores GCDH expression and enzyme activity in target tissues.
    evidence:
    - reference: PMID:38983872
      reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
      explanation: Supports restoration of the primary deficient enzymatic node by gene replacement therapy.
  - target: Brain exposure to toxic GA1 catabolites
    treatment_effect: INHIBITS
    description: Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.
    evidence:
    - reference: PMID:37075130
      reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches
      explanation: Supports inhibition of the downstream toxic-catabolite brain exposure pathway.
  evidence:
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the aminoadipate-semialdehyde synthase (Aass) gene.'
    explanation: Preclinical evidence for two liver-directed gene therapy strategies for GA1.
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
    explanation: Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination.
    explanation: Gene therapy prevents striatal neuropathology in the GA1 mouse model.
- name: Pharmacological chaperone therapy (investigational)
  description: 'Structure-targeted allosteric regulators are being explored as pharmacological chaperones for GA1 protein-misfolding variants, aiming to stabilize folded GCDH and increase residual enzyme function without competing with the natural substrate.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: GCDH protein misfolding
    treatment_effect: MODULATES
    description: Allosteric pharmacological chaperones are intended to stabilize folded GCDH protein and counter variant-associated misfolding.
    evidence:
    - reference: PMID:39312412
      reference_title: "Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Allosteric regulators acting as pharmacological chaperones hold promise for innovative therapeutics since they target noncatalytic sites and stabilize the folded protein without competing with the natural substrate, resulting in a net gain of function.
      explanation: The abstract describes the intended chaperone mechanism as stabilization of folded protein with gain of function.
  evidence:
  - reference: PMID:39312412
    reference_title: "Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Putative allosteric regulators were discovered using structure- and ligand-based virtual screening methods and validated using orthogonal biophysical and biochemical assays.
    explanation: Preclinical computational discovery followed by biochemical/biophysical validation supports investigational chaperone pharmacotherapy for GA1.
- name: Bezafibrate (investigational)
  description: 'The pan-PPAR agonist bezafibrate has shown neuroprotective effects in GCDH-deficient mice by normalizing oxidative stress and neuroinflammation in the striatum.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bezafibrate
      term:
        id: CHEBI:47612
        label: bezafibrate
  target_mechanisms:
  - target: Oxidative stress and neuroinflammation
    treatment_effect: INHIBITS
    description: Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
      explanation: Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.
  evidence:
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
    explanation: Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: bezafibrate should be tested as a potential adjuvant therapy for GA1.
    explanation: Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.

📚

References & Deep Research

References

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable

Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf

3 findings

NBS-identified and promptly treated individuals often avoid classic early striatal injury but still need long-term follow-up.

"In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for..."

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

Supports continued surveillance, including renal monitoring, despite prevention of classic early neurologic crises.

Standard care is combined metabolic therapy centered on lysine restriction, carnitine supplementation, and emergency illness management.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

Captures core treatment principles that structure current management recommendations.

Catabolic triggers should be proactively avoided in GA1 management plans.

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

Provides explicit avoidant-trigger guidance for sick-day and peri-procedural planning.

DOI:10.1002/jimd.12608

Exploring genotype–phenotype correlations in glutaric aciduria type 1

1 finding

Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).

"Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH)."

Show evidence (1 reference)

DOI:10.1002/jimd.12608 SUPPORT Human Clinical

"Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH)."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1007/s10545-011-9289-5

Diagnosis and management of glutaric aciduria type I – revised recommendations

1 finding

Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.

"Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria."

Show evidence (1 reference)

DOI:10.1007/s10545-011-9289-5 SUPPORT Other

"Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1021/acs.jmedchem.4c00292

Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1

1 finding

Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1

"Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1"

DOI:10.11588/heidok.00035789

New approaches in mathematical and data-based modeling for newborn screening

1 finding

New approaches in mathematical and data-based modeling for newborn screening

"New approaches in mathematical and data-based modeling for newborn screening"

DOI:10.1186/s13023-023-02833-z

Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China

1 finding

Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).

"Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH)."

Show evidence (1 reference)

DOI:10.1186/s13023-023-02833-z SUPPORT Human Clinical

"Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH)."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1186/s13052-025-01975-z

Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails

1 finding

Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.

"Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan."

Show evidence (1 reference)

DOI:10.1186/s13052-025-01975-z SUPPORT Human Clinical

"Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.7759/cureus.65722

Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report

1 finding

Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report

"Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report"

DOI:10.7759/cureus.86380

Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report

1 finding

Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report

"Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report"

DOI:10.1016/j.omtm.2024.101276

Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model

No top-level findings curated for this source.

DOI:10.3390/ijms241713158

Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1

No top-level findings curated for this source.

DOI:10.3390/ijns10040083

Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1

No top-level findings curated for this source.

Deep Research

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 48 citations 2026-05-08T19:29:56.789508

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Glutaryl-CoA Dehydrogenase Deficiency
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Glutaryl-CoA Dehydrogenase Deficiency covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Glutaryl‑CoA Dehydrogenase Deficiency (Glutaric Aciduria Type 1, GA1)

Executive summary

Glutaryl‑CoA dehydrogenase deficiency—commonly called glutaric aciduria type 1 (GA1)—is an autosomal recessive neurometabolic disorder of lysine, hydroxylysine, and tryptophan catabolism due to pathogenic variants in GCDH, leading to accumulation of glutaric acid (GA), 3‑hydroxyglutaric acid (3‑OH‑GA), and glutarylcarnitine (C5DC). The classic catastrophic outcome is acute or insidious striatal injury in early childhood with a severe dystonic movement disorder; critically, outcomes improve markedly with newborn screening (NBS) plus early dietary and emergency management, but false positives and false negatives (especially “low excretors”) remain important challenges. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4, zhou2023biochemicalandmolecular pages 1-2)

Abbreviations

GA1: glutaric aciduria type 1; GCDH: glutaryl‑CoA dehydrogenase; DBS: dried blood spot; MS/MS: tandem mass spectrometry; GC/MS: gas chromatography mass spectrometry; NBS: newborn screening; HE/LE: high/low excretor biochemical phenotypes; C5DC: glutarylcarnitine.

1. Disease information

1.1 What is the disease?

GA1 is a rare organic aciduria/neurometabolic disease caused by deficiency of mitochondrial glutaryl‑CoA dehydrogenase (GCDH), which is required for the catabolism of lysine, hydroxylysine, and tryptophan; deficiency leads to accumulation of GA, 3‑OH‑GA, glutaconic acid, and C5DC (detectable by GC/MS and MS/MS). (kolker2011diagnosisandmanagement pages 1-2, schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

Authoritative guideline definition (abstract quote): - “Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.” (Kölker et al., 2011, J Inherit Metab Dis, published 2011‑03; DOI:10.1007/s10545-011-9289-5; https://doi.org/10.1007/s10545-011-9289-5) (kolker2011diagnosisandmanagement pages 1-2) - “This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines).” (same abstract) (kolker2011diagnosisandmanagement pages 1-2)

1.2 Key identifiers (retrieved from current evidence)

Disease OMIM: 231670 (GA1) (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Causal gene: GCDH (gene OMIM 608801) (kolker2011diagnosisandmanagement pages 2-4)

Not retrieved in the current tool evidence set (will require external database lookup): MONDO ID, Orphanet ID, MeSH ID, ICD‑10/ICD‑11 codes.

1.3 Synonyms and alternative names

Glutaric aciduria type I / type 1 (GA‑I/GA1) (kolker2011diagnosisandmanagement pages 1-2)
Glutaric acidemia type I / type 1 (GA‑I/GA1) (kolker2011diagnosisandmanagement pages 1-2)
Glutaryl‑CoA dehydrogenase deficiency (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

1.4 Evidence provenance (patient vs aggregated)

The current evidence includes: - Aggregated resources/guidelines & literature syntheses: major clinical guideline (2011) and variant landscape/genotype–phenotype synthesis (2023). (kolker2011diagnosisandmanagement pages 1-2, schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2) - Population screening cohorts: large NBS program data (Germany; 2024) and provincial NBS cohort (China; 2023). (zaunseder2024digitaltierstrategyimproves pages 2-4, zhou2023biochemicalandmolecular pages 1-2) - Mechanistic/therapeutics research: protein misfolding characterization (2023) and emerging therapy preclinical studies (AAV; chaperones; 2024). (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2, mateubosch2024systemicdeliveryof pages 1-2, barroso2024useofthe pages 2-3) - Case reports to illustrate diagnostic pitfalls (2025). (gragnaniello2025diagnosisofglutaric pages 1-2, larancuent2025delayeddiagnosisof pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in GCDH, encoding mitochondrial glutaryl‑CoA dehydrogenase (FAD‑dependent homotetramer), impairing conversion of glutaryl‑CoA to crotonyl‑CoA. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

2.2 Risk factors

Genetic: autosomal recessive inheritance; population-specific founder variants reported (e.g., p.Ala421Val in Amish; IVS1+5G>T in Ojibwe; p.Arg402Trp relatively frequent in Europeans). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Physiologic/environmental triggers for neurologic crises: catabolic stressors including infectious illness, surgery, immunizations, fasting, and febrile illness, especially in early childhood. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4)

2.3 Protective factors

Early detection + combined metabolic management is protective against striatal injury, especially when initiated pre‑symptomatically. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 4-5)

2.4 Gene–environment interaction (clinical concept)

GA1’s major neurologic injury is strongly triggered by catabolic states (environment/physiology) interacting with the underlying enzymatic block. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 9-10)

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

Critical early-childhood neurologic vulnerability: Untreated GA1 typically causes neurologic disease during a finite early developmental window. The 2011 guideline summarizes that untreated GA‑I leads to neurologic disease in ~90% during 3–36 months, often after an encephalopathic crisis. (kolker2011diagnosisandmanagement pages 2-4)

Key phenotypes and suggested HPO terms (with evidence and typical timing): - Macrocephaly (HP:0000256): reported in ~75% of infants in guideline synthesis; can be early sign but non‑specific. (kolker2011diagnosisandmanagement pages 2-4) - Acute encephalopathic crisis / metabolic decompensation (e.g., HP:0002374 “Acute encephalopathy”): crises precipitated by infection/immunization/surgery; typical 3–36 months. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4) - Striatal/basal ganglia injury (radiologic/clinical correlate; e.g., HP:0002134 “Basal ganglia abnormality”): acute bilateral striatal injury following crises. (kolker2011diagnosisandmanagement pages 2-4) - Dystonia / complex movement disorder (HP:0001332): often severe, static, and disabling after striatal injury; dystonia on axial hypotonia is described as dominant. (kolker2011diagnosisandmanagement pages 2-4) - Developmental delay / motor delay (HP:0001263 / HP:0001270): transient early delay may occur; neuroregression can follow crises. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 2-4) - Seizures/status epilepticus (HP:0001250): may occur during decompensation; can contribute to mortality (case-based). (patil2024glutaricaciduriapresenting pages 1-2) - Characteristic neuroimaging: widened Sylvian fissures/frontotemporal atrophy are often noted; “macrocephaly and frontotemporal atrophy at birth” and widened Sylvian fissures are commonly cited. (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2, patil2024glutaricaciduriapresenting pages 1-2)

3.2 Severity, progression, and frequency notes

High morbidity/mortality without treatment: “Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality.” (Kölker et al., 2011 abstract) (kolker2011diagnosisandmanagement pages 1-2)
Insidious onset: guideline synthesis notes 10–20% may develop insidious/late onset without a documented crisis. (kolker2011diagnosisandmanagement pages 2-4)

3.3 Quality-of-life impact

Severe dystonia/complex movement disorder after striatal injury implies lifelong disability and dependence; direct standardized QoL instrument statistics were not retrieved in the current evidence set. (kolker2011diagnosisandmanagement pages 2-4)

4. Genetic / molecular information

4.1 Causal gene(s)

GCDH (chromosome 19p13.13/p13.2 reported across sources) encodes a 438 aa precursor with N‑terminal mitochondrial targeting sequence; mature enzyme is a FAD‑dependent homotetramer. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

4.2 Pathogenic variant spectrum

Scale of known pathogenic variation (recent synthesis): - A 2023 comprehensive genotype–phenotype study reports 421 different GCDH pathogenic variants identified and analyzed across 532 patients, with four novel variants listed. (Schuurmans et al., 2023; DOI:10.1002/jimd.12608; https://doi.org/10.1002/jimd.12608; published 2023‑04) (schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)

Variant types: mostly missense, with also nonsense, intronic variants, and deletions described in databases. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)

4.3 Biochemical subtypes (HE vs LE) and relation to residual activity

Patients are frequently grouped by urinary GA excretion: LE <100 mmol/mol creatinine vs HE >100 mmol/mol creatinine. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Reported correlation: variants with 0–2% or <5% residual activity tend to be HE; variants with 3–30% residual activity tend to be LE/low‑GA excretion. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Importantly, the 2011 guideline notes LE patients have the same risk of striatal injury as HE (i.e., biochemical “mildness” does not ensure clinical safety). (kolker2011diagnosisandmanagement pages 1-2)

4.4 Population variation and founder effects (examples)

Founder variants: p.Ala421Val (Amish) and IVS1+5G>T (Ojibwe) are highlighted; p.Arg402Trp is relatively frequent in Europeans. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Example regional spectrum (Fujian, China): among 35 unrelated patients, three variants represented ~73% of alleles; c.1244‑2A>C was predominant. (zhou2023biochemicalandmolecular pages 1-2)

4.5 Modifier genes / epigenetics / chromosomal abnormalities

No specific modifier genes, epigenetic mechanisms, or chromosomal abnormalities were retrieved in the current evidence set.

5. Environmental information

GA1 is a Mendelian disorder; “environmental” contributions primarily manifest as catabolic triggers for crises: - Intercurrent infections, immunization, surgery, fasting/febrile illness precipitating encephalopathic crises during a vulnerable developmental period. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4)

No toxin/pollution/infectious etiologic agent was indicated.

6. Mechanism / pathophysiology

6.1 Causal chain (biochemical → cellular → clinical)

Upstream trigger: inherited GCDH deficiency (loss of mitochondrial glutaryl‑CoA dehydrogenase function) in lysine/hydroxylysine/tryptophan catabolism. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Metabolic block: impaired conversion of glutaryl‑CoA → crotonyl‑CoA, leading to accumulation of glutaryl‑CoA and derivatives including GA and 3‑OH‑GA; secondary carnitine depletion and increased C5DC reflect conjugation/detoxification. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Neurotoxicity/energy impairment: accumulated organic acids are described to interfere with cerebral energy metabolism and contribute to neurologic injury. (patil2024glutaricaciduriapresenting pages 1-2)
Tissue vulnerability: during early development, catabolic stress can trigger an encephalopathic crisis, leading to bilateral striatal injury and a severe dystonic movement disorder. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 1-2)

6.2 Protein dysfunction and “misfolding disorder” concept (recent development)

A 2023 molecular study supports that many GA1 missense variants cause GCDH misfolding with altered oligomerization/tetramerization, reduced stability/solubility, increased aggregation, and loss of activity—supporting GA1 as a protein misfolding disorder and motivating pharmacological chaperone therapies. (Barroso et al., 2023; DOI:10.3390/ijms241713158; published 2023‑08; https://doi.org/10.3390/ijms241713158) (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

6.3 Pathways and ontology suggestions

Pathway concept: lysine degradation / amino‑acid catabolism in mitochondria (supported by disease definitions and biomarkers). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Suggested GO Biological Process terms (examples): lysine catabolic process; tryptophan catabolic process; mitochondrial fatty acid beta‑oxidation (context: acyl‑CoA dehydrogenase family); response to starvation; cellular response to oxidative stress (the latter not directly retrieved here).
Suggested GO Cellular Component: mitochondrion; mitochondrial matrix.
Suggested CL cell types: striatal medium spiny neuron (target of striatal injury); astrocyte and microglia (gliosis is reported in mouse gene therapy study outcomes). (mateubosch2024systemicdeliveryof pages 1-2)

6.4 Molecular profiling / omics

No transcriptomics/proteomics/metabolomics multi‑omics datasets were retrieved in the current evidence set.

7. Anatomical structures affected

7.1 Organ level

Central nervous system is the principal affected system, with the key lesion being striatal/basal ganglia injury. (kolker2011diagnosisandmanagement pages 2-4)

7.2 Tissue/cell level

Striatum / basal ganglia circuits: bilateral striatal injury is the neuropathological correlate of the movement disorder. (kolker2011diagnosisandmanagement pages 1-2)

7.3 Subcellular level

Mitochondria: GCDH is a mitochondrial enzyme; dysfunction is mitochondrial metabolic. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

7.4 Suggested UBERON terms

Striatum (UBERON:0002435)
Basal ganglion (UBERON:0002420)
Brain (UBERON:0000955)

8. Temporal development

8.1 Onset

Many infants are initially asymptomatic or show macrocephaly/transient delay early in life. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

8.2 Critical period and progression

A major “window of vulnerability” is infancy to early childhood; encephalopathic crises and striatal injury are concentrated in 3–36 months in guideline synthesis, and encephalopathic crises are described as rare after ~6 years. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 10-12)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive. (kolker2011diagnosisandmanagement pages 1-2)

9.2 Epidemiology (recent data prioritized)

Fujian Province, China (2014–2022): incidence 1 in 63,948 based on 1,151,069 screened and 18 NBS diagnoses. (Zhou et al., 2023, Orphanet J Rare Dis, published 2023‑07; DOI:10.1186/s13023-023-02833-z; https://doi.org/10.1186/s13023-023-02833-z) (zhou2023biochemicalandmolecular pages 1-2)
Germany (Heidelberg NBS context): cited birth prevalence 1:135,000. (Zaunseder et al., 2024, Int J Neonatal Screen, published 2024‑12; DOI:10.3390/ijns10040083; https://doi.org/10.3390/ijns10040083) (zaunseder2024digitaltierstrategyimproves pages 1-2)
Broad synthesis: prevalence varies widely (~1:125,000 general to ~1:250 high‑risk groups). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

9.3 Carrier frequency / penetrance / expressivity

Not quantified in the current evidence set; GA1 shows variable expressivity and incomplete genotype–phenotype correlation (see Section 4). (schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)

10. Diagnostics

10.1 Core biochemical markers

Screening marker (DBS, MS/MS): C5DC (glutarylcarnitine). (kolker2011diagnosisandmanagement pages 4-5, zhou2023biochemicalandmolecular pages 1-2)
Confirmatory urine organic acids (GC/MS): elevated GA and 3‑OH‑GA. (kolker2011diagnosisandmanagement pages 4-5, zhou2023biochemicalandmolecular pages 1-2)

10.2 Confirmatory genetic/enzyme testing

The 2011 guideline recommends diagnosis by: - Quantitative GA/3‑OH‑GA, plus GCDH mutation analysis (reported sensitivity 98–99%), and/or enzyme analysis; enzyme activity testing in fibroblasts/leukocytes is described as the “gold standard” for confirmation. (kolker2011diagnosisandmanagement pages 7-8)

10.3 Newborn screening implementation and performance (real‑world)

Heidelberg (Germany) program (2014–2021): reported sensitivity 100%, specificity 99.94%, false‑positive rate 0.06%, PPV 1.5%. (zaunseder2024digitaltierstrategyimproves pages 2-4)

False positives and follow‑up: In the Heidelberg suspected‑diagnosis set, urinary 3‑OH‑GA excluded GA1 in 90% of false positives; 7% had elevated 3‑OH‑GA prompting additional genetic/enzymatic work‑up. (zaunseder2024digitaltierstrategyimproves pages 5-7)

Recent development (2024): digital‑tier machine learning to reduce GA1 NBS false positives. The Heidelberg group reports that a digital‑tier strategy using logistic regression/ridge regression/SVM can reduce false positives by >90% while retaining case detection; e.g., reducing test‑set false positives from 235 → 16 (LR trained on full set) or 235 → 18 (LR trained on suspected set) with 100% sensitivity. (zaunseder2024digitaltierstrategyimproves pages 1-2, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)

10.4 False negatives and “low excretor” challenge

Low excretors can have normal C5DC in DBS and normal urine GA/3‑OH‑GA, causing false‑negative NBS, and may require diagnosis via clinical suspicion + MRI + molecular testing. (gragnaniello2025diagnosisofglutaric pages 1-2)
A delayed-diagnosis case-based review emphasizes that biochemical markers may be “within normal limits” and that exome sequencing can establish diagnosis when biomarkers/imaging are inconclusive. (larancuent2025delayeddiagnosisof pages 1-2)

10.5 Differential diagnosis

Not comprehensively retrieved from the current evidence set; in practice includes other organic acidurias and basal ganglia injury disorders.

11. Outcome / prognosis

11.1 Prognosis with vs without early treatment

Guideline-level evidence supports strong benefit of early diagnosis and combined therapy: - “It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment.” (Kölker et al., 2011 abstract) (kolker2011diagnosisandmanagement pages 1-2) - The guideline also states: “initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage.” (same abstract) (kolker2011diagnosisandmanagement pages 1-2)

11.2 Residual risk despite early treatment

A 2023 review notes that, despite improved outcomes with NBS and therapy, 15–23% of early-treated patients may still experience encephalopathic crises. (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

12. Treatment

12.1 Standard of care (authoritative guideline)

The 2011 revised recommendations emphasize: - Maintenance therapy: low‑lysine diet (often with lysine‑free/tryptophan‑reduced amino acid supplements) plus L‑carnitine supplementation; recommended especially during the 0–6 year vulnerability window. (kolker2011diagnosisandmanagement pages 8-9, kolker2011diagnosisandmanagement pages 7-8) - Emergency therapy: prompt, aggressive treatment during febrile illness/surgery/immunization; includes high‑energy carbohydrate intake, temporary natural protein reduction/omission for 24–48 h with staged reintroduction, and increased carnitine dosing with careful monitoring. (kolker2011diagnosisandmanagement pages 9-10, kolker2011diagnosisandmanagement pages 10-12)

Guideline quote supporting comparative importance: - “It showed for the first time that both basic metabolic treatment (low lysine diet, carnitine supplementation) and emergency treatment were clearly beneficial for patients diagnosed by newborn screening.” (kolker2011diagnosisandmanagement pages 4-5) - “The beneficial effect of emergency treatment was more pronounced than that of maintenance treatment.” (kolker2011diagnosisandmanagement pages 4-5)

12.2 Evidence of real-world implementations

NBS-linked metabolic care is implemented in multiple countries/centers; large NBS datasets show confirmatory workflows and follow-up testing (e.g., urine 3‑OH‑GA confirmation in Heidelberg). (zaunseder2024digitaltierstrategyimproves pages 5-7)

12.3 Emerging therapies (2023–2024 prioritized)

(A) Gene replacement therapy (preclinical)

A 2024 preclinical study reports systemic AAV9‑GCDH delivery in Gcdh−/− mice: - Neonatal systemic AAV‑GCDH restored hepatic and striatal GCDH activity and prevented high‑lysine‑diet induced lethality (~60% death in untreated KO vs complete survival with neonatal gene therapy), reduced brain metabolite accumulation, and protected against striatal injury on MRI and pathology. (Mateu‑Bosch et al., 2024‑09; DOI:10.1016/j.omtm.2024.101276; https://doi.org/10.1016/j.omtm.2024.101276) (mateubosch2024systemicdeliveryof pages 1-2)

(B) Pharmacological chaperones / allosteric stabilizers (structure-guided discovery)

A 2024 Journal of Medicinal Chemistry study applies a site‑directed enzyme enhancement therapy (SEE‑Tx) computational platform to identify allosteric pharmacological chaperones (structure‑targeted allosteric regulators) for GCDH: - Virtual screening of ~2.7 million compounds, experimental validation hit rate >20%, and multiple validated binders (one with Kd 3.4 μM) that increased stability and/or activity in biochemical assays—supporting feasibility of small-molecule rescue strategies for misfolding variants. (Barroso et al., 2024‑09; DOI:10.1021/acs.jmedchem.4c00292; https://doi.org/10.1021/acs.jmedchem.4c00292) (barroso2024useofthe pages 10-10, barroso2024useofthe pages 2-3)

12.4 MAXO suggestions (examples)

Dietary lysine restriction (MAXO: dietary modification)
Emergency metabolic decompensation management (MAXO: emergency treatment)
Levocarnitine supplementation (MAXO: supplementation)
Gene therapy (AAV-mediated gene transfer) (MAXO: gene therapy)

13. Prevention

Secondary prevention: NBS programs detect GA1 before symptoms; guideline-level evidence indicates early detection + treatment can prevent striatal injury in most neonatally diagnosed cases. (kolker2011diagnosisandmanagement pages 1-2)
Tertiary prevention: strict emergency protocols during illness/surgery/immunization reduce risk of acute striatal injury in vulnerable period. (kolker2011diagnosisandmanagement pages 9-10, kolker2011diagnosisandmanagement pages 10-12)

14. Other species / natural disease

No naturally occurring GA1 in non-human species was retrieved in the current evidence set.

15. Model organisms

15.1 Mouse model (genetic)

Gcdh knockout mouse challenged with high‑lysine diet is used to model provoked metabolic injury and test therapeutics; AAV9‑GCDH gene therapy demonstrates prevention of lethality and striatal pathology, supporting translational development. (mateubosch2024systemicdeliveryof pages 1-2, mateubosch2024systemicdeliveryof pages 6-7)

15.2 Suggested applications and limitations

Application: evaluate metabolite‑driven neurotoxicity and CNS-targeting gene replacement strategies.
Limitation (from gene therapy study): CNS transduction is much higher with neonatal dosing; adult dosing yields poor CNS expression, highlighting developmental constraints. (mateubosch2024systemicdeliveryof pages 6-7)

Key quantitative evidence table

The following table compiles major statistics (epidemiology, screening performance, variant frequencies, and emerging therapies) from the retrieved sources.

Topic	Metric/Result	Population/Study	Year	PMID or DOI	URL	Evidence type	Citation
Epidemiology	Worldwide frequency about 1 in 100,000 births	General/global estimate summarized in GA1 molecular review	2023	DOI: 10.3390/ijms241713158	https://doi.org/10.3390/ijms241713158	Review/mechanistic human disease summary	(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Epidemiology	Prevalence ranges from ~1:125,000 in general populations to ~1:250 in high-risk groups	Literature synthesis in genotype-phenotype study	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human literature synthesis	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)
Epidemiology	Estimated birth prevalence in Germany 1:135,000	Heidelberg NBS program background	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 1-2)
Epidemiology	Incidence 1 in 63,948 newborns	Fujian Province, China; 1,151,069 screened, 18 newborns diagnosed	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human NBS cohort	(zhou2023biochemicalandmolecular pages 1-2)
Disease burden/outcomes	Despite early treatment, 15–23% of patients still experience encephalopathic crises	Review of treated early-diagnosed GA1	2023	DOI: 10.3390/ijms241713158	https://doi.org/10.3390/ijms241713158	Review/outcomes summary	(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Genetics	421 distinct pathogenic GCDH variants identified; phenotypes aggregated from 532 patients	Large genotype-phenotype analysis	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human literature synthesis/genetics	(schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)
Genetics	Variant databases listed 240 pathogenic variants in LOVD and 232 in ClinVar	Database-informed genotype review	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human genetics/database synthesis	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Biochemical phenotype	High excretors (HE): urinary GA >100 mmol/mol creatinine; Low excretors (LE): <100 mmol/mol creatinine	Standard GA1 biochemical classification	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human biochemical genetics	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Residual enzyme activity	HE usually associated with residual activity 0–2% or <5%; LE with 3–30% residual activity	Genotype-biochemistry correlations across reports	2023	DOI: 10.1002/jimd.12608; DOI: 10.3390/ijms241713158	https://doi.org/10.1002/jimd.12608 ; https://doi.org/10.3390/ijms241713158	Human genetics/mechanistic review	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Fujian molecular spectrum	71 variants across 70 alleles; 19 pathogenic variants identified	35 unrelated GA1 patients from Fujian	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	c.1244-2A>C accounted for 63.38% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	p.Ala421Thr (c.1261G>A) accounted for 5.63% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	p.Gly136Cys (c.406G>T) accounted for 4.22% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common genotype	Homozygous c.[1244-2A>C];[1244-2A>C] in 18/35 (52.43%) patients	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Excretor distribution	28 HE and 5 LE patients	Fujian cohort with urine GA classification	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/biochemical	(zhou2023biochemicalandmolecular pages 1-2)
NBS program size	Initial extraction 1,055,885 profiles; analytic dataset 1,025,953 profiles; 494 suspected GA1 after cleaning	Heidelberg NBS study	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 2-4)
NBS performance	Sensitivity 100%, specificity 99.94%, false-positive rate 0.06%, PPV 1.5%	Heidelberg GA1 NBS program (2014–2021)	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 2-4)
Fujian NBS performance	265 screen-positive newborns; positivity 0.023%; PPV 6.42% (17/265)	Fujian NBS cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human NBS cohort	(zhou2023biochemicalandmolecular pages 1-2)
NBS sex effect	False positives: 326/485 (67%) male vs 159/485 (33%) female; confirmed GA1 4 male / 5 female	Heidelberg suspected-diagnosis set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 5-7, zaunseder2024digitaltierstrategyimproves pages 4-5)
Screening biomarker levels	Mean Glut: GA1 2.698 ± 1.548 µmol/L; suspected-not-confirmed 0.526 ± 0.106 µmol/L; normal 0.157 ± 0.057 µmol/L	Heidelberg NBS metabolite distributions	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/biomarker study	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Excretor biomarker levels	Mean Glut in LE 1.9 ± 1.28 µmol/L (n=6) vs HE 4.3 ± 0.2 µmol/L (n=3)	Heidelberg confirmed GA1 cases	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/biomarker study	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Confirmatory follow-up	Urinary 3-OH-GA excluded GA1 in 90% (435/485) false positives; 7% (34/485) had elevated urinary 3-OH-GA prompting more testing	Heidelberg follow-up after positive NBS	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS follow-up program	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Digital-tier NBS improvement	False positives reduced from 235 to 16 on test set (93.19% reduction) with LR model trained on full dataset; 100% sensitivity maintained	Heidelberg independent test set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/machine learning	(zaunseder2024newapproachesin pages 76-80, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)
Digital-tier NBS improvement	False positives reduced from 235 to 18 on test set (92.34% reduction) with LR model trained on suspected-diagnosis dataset; 100% sensitivity maintained	Heidelberg independent test set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/machine learning	(zaunseder2024digitaltierstrategyimproves pages 8-10, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)
Traditional vs digital-tier specificity	Traditional test-set screening: 0 FN, 235 FP, sensitivity 100%, specificity 99.90%	Heidelberg test set	2024	DOI: 10.11588/heidok.00035789	https://doi.org/10.11588/heidok.00035789	NBS program/modeling thesis	(zaunseder2024newapproachesin pages 76-80)
False-negative risk	NBS sensitivity reported as 93.3% and specificity 99.42% in a delayed-diagnosis report discussing missed cases	Case-based review of diagnostic performance	2025	DOI: 10.7759/cureus.86380	https://doi.org/10.7759/cureus.86380	Case report/review	(larancuent2025delayeddiagnosisof pages 5-7)
Low-excretor frequency	LE phenotype estimated in 30–40% of GA1 patients	Diagnostic review/case report	2025	DOI: 10.7759/cureus.86380	https://doi.org/10.7759/cureus.86380	Case report/review	(larancuent2025delayeddiagnosisof pages 2-3)
AAV gene therapy	Untreated KO mice under HLD had ~60% death; neonatal AAV-GCDH yielded complete survival after HLD challenge	Gcdh knockout mouse model	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 1-2)
AAV biodistribution/transduction	Neonatal delivery produced ~40-fold more striatal viral genomes at 1 month than later treatment	AAV9-GCDH in Gcdh knockout mice	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 6-7)
AAV dosing	Systemic doses evaluated included about 7.5×10^12 vg/kg up to ~5×10^13 vg/kg	AAV9-GCDH preclinical optimization	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 6-7)
Pharmacological chaperone discovery	Virtual screening of ~2.7 million compounds yielded ~2,200 candidates; 94 compounds purchased for follow-up	SEE-Tx GCDH allosteric screen	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 10-10)
Pharmacological chaperone discovery	Hit rate >20% in experimental validation	SEE-Tx GCDH chaperone campaign	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 10-10)
Pharmacological chaperone potency	One lead bound GCDH with Kd = 3.4 µM; additional validated binders 6.9–44.9 µM range reported for examples	SEE-Tx validated allosteric regulators	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 9-10, barroso2024useofthe pages 2-3)

Table: This table compiles key quantitative findings for glutaric acidemia type 1, including epidemiology, newborn screening performance, variant frequencies, and emerging therapy results. It is designed as a quick-reference evidence summary for a disease knowledge base entry.

Visual evidence (newborn screening performance)

Table 2 from Zaunseder et al. (2024) provides the detailed sensitivity/specificity and false-positive reductions achieved by the digital-tier ML strategy (e.g., 235 → 16/18 false positives on the independent test set with maintained sensitivity), supporting the quantitative claims in Section 10. (zaunseder2024digitaltierstrategyimproves media 0bbb340b)

Notes on evidence gaps (from current tool retrieval)

MONDO/Orphanet/MeSH/ICD identifiers were not directly retrieved in the current evidence set and should be populated via dedicated ontology/database queries.
No high-quality, GA1-specific 2023–2024 human interventional clinical trials were retrieved here; emerging therapies are currently supported primarily by preclinical studies and structure-guided discovery.
QoL instrument data and formal differential diagnosis lists were not retrieved in the current evidence set.

References

(kolker2011diagnosisandmanagement pages 1-2): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 2-4): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zhou2023biochemicalandmolecular pages 1-2): Jinfu Zhou, Guilin Li, Lin Deng, Peiran Zhao, Yinglin Zeng, Xiaolong Qiu, Jinying Luo, and Liangpu Xu. Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from fujian province, southeastern china. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02833-z, doi:10.1186/s13023-023-02833-z. This article has 7 citations and is from a peer-reviewed journal.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 2-4): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2): Madalena Barroso, Marcus Gertzen, Alexandra F. Puchwein-Schwepcke, Heike Preisler, Andreas Sturm, Dunja D. Reiss, Marta K. Danecka, Ania C. Muntau, and Søren W. Gersting. Glutaryl-coa dehydrogenase misfolding in glutaric acidemia type 1. International Journal of Molecular Sciences, 24:13158, Aug 2023. URL: https://doi.org/10.3390/ijms241713158, doi:10.3390/ijms241713158. This article has 5 citations.
(mateubosch2024systemicdeliveryof pages 1-2): Anna Mateu-Bosch, Eulàlia Segur-Bailach, Emma Muñoz-Moreno, María José Barallobre, Maria Lourdes Arbonés, Sabrina Gea-Sorlí, Frederic Tort, Antonia Ribes, Judit García-Villoria, and Cristina Fillat. Systemic delivery of aav-gcdh ameliorates hld-induced phenotype in a glutaric aciduria type i mouse model. Molecular Therapy - Methods & Clinical Development, 32:101276, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101276, doi:10.1016/j.omtm.2024.101276. This article has 10 citations.
(barroso2024useofthe pages 2-3): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.
(gragnaniello2025diagnosisofglutaric pages 1-2): Vincenza Gragnaniello, Andrea Puma, Daniela Gueraldi, Ignazio D’Errico, Chiara Cazzorla, Christian Loro, Elena Porcù, Leonardo Salviati, and Alberto B. Burlina. Diagnosis of glutaric aciduria type i based on neuroradiological findings: when neonatal screening fails. Italian Journal of Pediatrics, May 2025. URL: https://doi.org/10.1186/s13052-025-01975-z, doi:10.1186/s13052-025-01975-z. This article has 0 citations and is from a peer-reviewed journal.
(larancuent2025delayeddiagnosisof pages 1-2): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 4-5): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 9-10): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(patil2024glutaricaciduriapresenting pages 1-2): Manojkumar G Patil, Neha Tyagi, Om Prasanth Reddy Avuthu, and Shradha Salunkhe. Glutaric aciduria presenting with an acute encephalitic crisis: a case report. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.65722, doi:10.7759/cureus.65722. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 10-12): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 1-2): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 7-8): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 5-7): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024digitaltierstrategyimproves pages 7-8): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024digitaltierstrategyimproves media 0bbb340b): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 8-9): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(barroso2024useofthe pages 10-10): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.
(mateubosch2024systemicdeliveryof pages 6-7): Anna Mateu-Bosch, Eulàlia Segur-Bailach, Emma Muñoz-Moreno, María José Barallobre, Maria Lourdes Arbonés, Sabrina Gea-Sorlí, Frederic Tort, Antonia Ribes, Judit García-Villoria, and Cristina Fillat. Systemic delivery of aav-gcdh ameliorates hld-induced phenotype in a glutaric aciduria type i mouse model. Molecular Therapy - Methods & Clinical Development, 32:101276, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101276, doi:10.1016/j.omtm.2024.101276. This article has 10 citations.
(zaunseder2024digitaltierstrategyimproves pages 4-5): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024newapproachesin pages 76-80): Elaine Serena Zaunseder. New approaches in mathematical and data-based modeling for newborn screening. Text, Jan 2024. URL: https://doi.org/10.11588/heidok.00035789, doi:10.11588/heidok.00035789. This article has 0 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 8-10): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(larancuent2025delayeddiagnosisof pages 5-7): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(larancuent2025delayeddiagnosisof pages 2-3): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(barroso2024useofthe pages 9-10): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Disease Characteristics Report: Glutaryl‑CoA Dehydrogenase Deficiency (Glutaric Aciduria Type 1, GA1)

Executive summary

Abbreviations

1. Disease information

1.1 What is the disease?

1.2 Key identifiers (retrieved from current evidence)

1.3 Synonyms and alternative names

1.4 Evidence provenance (patient vs aggregated)

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interaction (clinical concept)

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

3.2 Severity, progression, and frequency notes

3.3 Quality-of-life impact

4. Genetic / molecular information

4.1 Causal gene(s)

4.2 Pathogenic variant spectrum

4.3 Biochemical subtypes (HE vs LE) and relation to residual activity

4.4 Population variation and founder effects (examples)

4.5 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (biochemical → cellular → clinical)

6.2 Protein dysfunction and “misfolding disorder” concept (recent development)

6.3 Pathways and ontology suggestions

6.4 Molecular profiling / omics

7. Anatomical structures affected

7.1 Organ level

7.2 Tissue/cell level

7.3 Subcellular level

7.4 Suggested UBERON terms

8. Temporal development

8.1 Onset

8.2 Critical period and progression

9. Inheritance and population

9.1 Inheritance

9.2 Epidemiology (recent data prioritized)

9.3 Carrier frequency / penetrance / expressivity

10. Diagnostics

10.1 Core biochemical markers

10.2 Confirmatory genetic/enzyme testing

10.3 Newborn screening implementation and performance (real‑world)

10.4 False negatives and “low excretor” challenge